Sijibio Obtains Approval for Brain Thrombectomy Stent 'Tromba'... First Domestic Success

Sijibio thrombus removal stent Tromba.

[Asia Economy Reporter Lee Gwan-joo] Siji Bio announced on the 13th that it has obtained manufacturing approval for the thrombectomy stent 'Tromba.' This marks a significant milestone as the first successful domestic production of thrombectomy stents, which had previously relied entirely on imported products.

Cerebral vascular stents are essential devices used in the treatment of stroke. The domestic cerebral vascular stent market is approximately 31.9 billion KRW, with the thrombectomy stent market at about 8.4 billion KRW and the cerebral aneurysm stent market at about 23.5 billion KRW. However, there have been no domestic products in the market so far, with all products being imported.

The newly approved Tromba is a retrievable stent used in the treatment of acute cerebral infarction. It removes blood clots to restore blood flow in patients with ischemic stroke caused by occlusion of intracranial vessels due to thrombosis, especially those who are unsuitable for or have failed treatment with the vascular thrombolytic agent plasminogen activator (t-PA).

The stent features a 'helical plate' structure, combining a straight wire coiled into a spiral, providing high flexibility that allows it to navigate curved blood vessels. It also incorporates radiopaque wires woven into the stent, enabling confirmation of the procedure results through radiographic imaging after the intervention.

With the approval of Tromba, Siji Bio has established the first domestic cerebral vascular stent portfolio among Korean medical device companies, including the 'Alpha Stent (α-stent)' for cerebral aneurysm treatment, which was successfully developed in 2019.

Yoo Hyun-seung, CEO of Siji Bio, stated, "Following the Alpha Stent, the domestic first development of the thrombectomy stent Tromba represents consecutive achievements, allowing us to build the first cerebral vascular stent portfolio among Korean medical device companies. We will continue to develop next-generation stents to contribute to the localization of imported products and provide excellent and reasonable treatment options to patients with cerebral vascular diseases."

This content was produced with the assistance of AI translation services.